Investigational drug · Phase 2
Kylo-11
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Lipoprotein Disorder.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "Kylo-11"
First trial start
2025
Oct 29, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Kylo-11", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lipoprotein Disorder
Largest trials
Live from ClinicalTrials.gov: studies naming "Kylo-11" as an intervention, largest first.
- Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)Pivotal-lookingActive, not recruiting
Kylonova (Xiamen) Biopharma co., LTD.Industry
NCT07327840 · 204 participants (planned) · Start Oct 29, 2025 · Primary completion Sep 30, 2026
Drug: Kylo-11 or matched placebo · For: Lipoprotein Disorder
Sites: Los Angeles, California; Oxnard, California; San Diego, California · 48 sites in all
Kylonova (Xiamen) Biopharma co., LTD.Industry
NCT06363851 · 71 participants · Start May 16, 2024 · Primary completion Jun 17, 2025
Drug: Kylo-11; Placebo · For: Cardiovascular Diseases
Sites: Chengdu, China
Newest research
PubMed records naming it or its code names, newest first.
- Deep and durable lipoprotein(a) lowering: Kylo-11 advances RNA interference therapeutics.
Rosenson RS, Goonewardena SN · Lancet 2026
- Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
Sarraju A, Du X, Zhou L, et al. · Lancet 2026
Also in development for Lipoprotein Disorder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.